3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
4
Phase NA
1
Phase 4
1
Phase 3
1
Phase 1/2
1
Phase 1
1
Status
Withdrawn
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Breast Neoplasms
3
Neoplasms
2
NSCLC
2
Lymphoma, Non-Hodgkin
2
Carcinoma, Non-Small-Cell Lung
2
Adenocarcinoma
2
Solid Tumor Regardless of Localization and Stage
1
Patient Acceptance of Health Care
1
Pancreatic Neoplasms
1
Pain
1
Oropharyngeal Neoplasms
1
Neoplasms, Second Primary
1
Multiple Myeloma
1
Lymphoma, Extranodal NK-T-Cell
1
Localized Advanced Rectal Adenocarcinoma
1
Liver Neoplasms
1
HER-2 Negative Breast Cancer
1
Gastrointestinal Neoplasms
1
Esophageal Neoplasms
1
Colorectal Neoplasms
1
Acute Kidney Injury
1
Interventions
Radiofrequency Ablation
4
gadolinium ethoxybenzyl DTPA
2
atezolizumab
2
Sorafenib
2
Oxaliplatin
2
Fluorouracil
2
Dexmedetomidine
2
Bevacizumab
2
voxilaprevir
1
velpatasvir
1
huachansu
1
entecavir
1
Tobacco Use Cessation Devices
1
Tinzaparin
1
Telbivudine
1
Technetium Tc 99m Aggregated Albumin
1
Sofosbuvir
1
Sevoflurane
1
Ribavirin
1
Radionuclide Generators
1
Psychiatric Rehabilitation
1
Propofol
1
Pregabalin
1
Polymerase Chain Reaction
1
Nivolumab
1
Neuroleptanalgesia
1
Lamivudine
1
Immunotherapy
1
Gene Expression Profiling
1
Galactose
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 4
×
Liver Neoplasms
×
Drug Therapy
×
Clear all
NCT00510627
2017-03-03
Prometheus
Boston Scientific Corporation
Phase 4
Withdrawn